PIK3CG and glioblastoma: Another preclinical trial showed sonic Hh and PI3K pathways were activated in PTEN‐deficient glioblastoma, simultaneously targeting both pathways resulted in markedly growth reduction of PTEN‐deficient glioblastomas.645